MEDVi Review

MEDVi — Provider Profile

April 2026 context: This provider is active. Orforglipron (Eli Lilly oral GLP-1) is not yet FDA-approved — PDUFA date April 10, 2026. Medicare GLP-1 Bridge coverage for obesity is pending. Compounded semaglutide supply is declining under FDA enforcement pressure.

Overview

MEDVi is a physician-led telehealth platform founded in 2022, focused on weight management and metabolic health. The company positions itself as a "concierge-level" telehealth service — meaning more frequent physician touchpoints and metabolic coaching than budget providers, while still operating at a lower price point than premium clinical programs like Calibrate or Sequence.

The core offering bundles board-certified physician consultations, medication management, and metabolic health coaching into a single monthly subscription. MEDVi focuses on brand-name GLP-1 medications through insurance, with orforglipron expected to become the primary cash-pay option if FDA approves it on April 10, 2026. Compounded supply remains available but is declining under enforcement pressure.

April 2026 context: The compounded GLP-1 market is under active FDA enforcement pressure, with supply declining as enforcement actions continue (503B compliance deadlines passed in 2025). MEDVi's value proposition rests on its branded medication access, insurance navigation, bundled coaching model, and orforglipron at $149/month — pending FDA approval (PDUFA April 10, 2026) as the cash-pay budget option. With every telehealth platform now offering the same branded medications, MEDVi's frequent physician follow-ups and metabolic coaching are the genuine differentiators. CagriSema remains pending FDA approval and could expand MEDVi's medication menu.

It is worth noting that MEDVi is a relatively young company with a limited public track record. The "concierge" branding may overstate the degree of personalization compared to true concierge medicine practices — though the included coaching and frequent follow-ups do exceed what most telehealth competitors offer.

Medications Offered

• Brand Wegovy (semaglutide) — Available via insurance. Includes Wegovy HD (7.2mg dose, not yet FDA-approved as of April 2026)
• Brand Zepbound (tirzepatide) — Available via insurance
• Orforglipron (oral GLP-1) — Not yet FDA-approved (PDUFA April 10, 2026). Expected at $149/mo if approved. Daily oral pill, no injections.
• Compounded semaglutide / tirzepatide — Availability declining under ongoing FDA enforcement actions (503B compliance deadlines passed 2025)

Pricing

True monthly cost: MEDVi's pricing has shifted with the loss of compounded options. Orforglipron at $149/month (plus MEDVi's program fee for physician visits and coaching) is now the primary cash-pay pathway. For patients with insurance coverage for brand-name injectables, the total cost is MEDVi's program fee plus your insurance copay. The bundled coaching and frequent physician follow-ups remain the core differentiator — most competitors prescribing orforglipron or brand-name injectables don't include this level of clinical support.

Lab work is still not included in the program — an additional out-of-pocket expense.

States Served

Available in 47 US states. The service is entirely virtual — no in-person visits required.

Insurance

• Brand-name GLP-1 medications (Wegovy, Zepbound) can be covered through insurance
• Medicare Bridge Program: Medicare patients can access GLP-1s at $50/month copay (expected 2026, pending)
• Orforglipron is cash-pay ($149/mo through the manufacturer)
• HSA/FSA cards accepted

Consultation Process

Model: Video consultations with board-certified physicians.

1. Complete an online intake form covering medical history, weight goals, and current medications
2. Schedule a video consultation with a board-certified physician
3. Physician determines medication eligibility and develops a treatment plan
4. Medication ships to the patient
5. Follow-up video visits every 4-6 weeks, included in the program fee
6. Monthly metabolic health coaching sessions, also included

The video-based model with scheduled follow-ups every 4-6 weeks is more frequent than what most telehealth competitors offer. However, MEDVi's physicians are board-certified in general practice — not specifically obesity medicine specialists, which platforms like Mochi Health and Sequence emphasize.

Pros

• Video consultations with board-certified physicians — not async questionnaires
• Brand-name GLP-1 medications available; orforglipron ($149/mo announced) expected upon FDA approval (PDUFA April 10, 2026)
• Metabolic health coaching included at no extra cost
• Follow-up visits every 4-6 weeks — more frequent than most telehealth competitors
• Broad state coverage (47 states)
• Insurance accepted for brand-name medications
• HSA/FSA eligible
• Bundled pricing — no hidden membership fees

Cons

• Compounded GLP-1 options permanently unavailable — all patients have transitioned to branded alternatives
• Lab work not included in the program — an additional out-of-pocket expense
• Founded in 2022 with a limited public track record compared to established competitors
• Physicians are not specifically obesity medicine specialists
• The "concierge" branding may set expectations higher than the actual level of personalization
• Not available in all 50 states

Best For

Patients who want more hands-on clinical support than a basic prescription service but don't want to pay premium prices ($400+/month) for programs like Calibrate. MEDVi fills a mid-market niche: the included physician video visits every 4-6 weeks and metabolic coaching provide meaningfully more touchpoints than budget platforms, at a moderate cost premium.

This is a reasonable option for patients who value regular physician check-ins and want the flexibility of both orforglipron (cash-pay oral option) and brand-name injectable GLP-1s through insurance under one provider.

Editorial Verdict

MEDVi sits in the mid-market tier of GLP-1 telehealth — more clinical depth than basic prescription platforms, but more affordable than premium programs like Calibrate or Sequence. In the post-compounding market, where most providers offer the same branded medications, MEDVi's value proposition has shifted to its bundled coaching and frequent physician follow-ups as the core differentiator.

With compounded options under significant regulatory pressure, the pricing calculus is settled. Orforglipron at $149/month (plus MEDVi's program fee) is the cash-pay floor — and with 14+ months of real-world data, orforglipron's efficacy and tolerability profile is well-established. Whether MEDVi's coaching and follow-up premium is worth it depends on how much you value regular video check-ins with a physician and monthly coaching sessions. For patients who are self-motivated and just need an orforglipron prescription, going through a simpler platform will cost less. For patients who want structured support without the $199+/month program fee of Calibrate, MEDVi remains a credible middle option.

The main caution remains company maturity. MEDVi is now three years old, and its successful navigation of the compounding transition — pivoting to branded medications without major service disruptions — demonstrates operational resilience. However, it still lacks the track record of established players. The providers are board-certified physicians but not obesity medicine specialists specifically — a distinction that may matter to patients with complex metabolic conditions. CagriSema, still pending FDA approval, could expand the medication menu further. If specialist credentials are important to you, Mochi Health or Sequence are worth comparing.

Related Content

• Starting GLP-1 in 2026 — Updated guide for new patients
• Best Oral GLP-1 Options 2026 — Orforglipron and oral Wegovy compared
• Medicare GLP-1 Coverage Guide — Medicare Bridge Program details
• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• Cheapest GLP-1 Providers — Budget options compared
• GLP-1 Cost & Insurance FAQ — What you'll actually pay

MEDVi GLP-1 Review: Is the "Concierge" Telehealth Model Worth It?

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Our rating: 3.5/5

MEDVi positions itself as "concierge-level" GLP-1 telehealth — more clinical depth than budget platforms, at a lower price than premium programs like Calibrate. MEDVi offers genuine value in its bundled coaching model, but the "concierge" label is aspirational, and there are legitimate concerns about the company's maturity and mixed patient reviews.

Editorial Independence Note: Telehealth Ally does not accept payment from providers for placement or ranking. This review is independently researched. See our editorial policy for details.

What does MEDVi offer?

MEDVi provides compounded and brand-name GLP-1 medications through a subscription that bundles medication, physician consultations, and metabolic coaching into a single monthly price.

How much does MEDVi cost per month?

MEDVi charges $199/month for compounded semaglutide and $349/month for compounded tirzepatide — both prices include physician visits and metabolic coaching, with no separate membership fee. MEDVi's pricing structure is all-inclusive for the compounded programs — one price covers physician visits, medication, and coaching. No separate membership fee.

Pricing last verified April 2026. We update pricing data monthly. Contact us if you spot an error.

How does MEDVi pricing compare to other providers?

The honest assessment: At $199/month, MEDVi is $50/month more than Ro and $80/month more than Henry Meds for compounded semaglutide. The premium gets you video physician consultations and metabolic coaching — services that Ro and Henry Meds don't offer. Whether that's worth $50/month depends on how much you value face-to-face clinical interaction.

Compared to Mochi Health (~$178/month all-in with dietitian access), MEDVi costs slightly more but offers physician-led video visits rather than Mochi's broader dietitian + physician model. Compared to Calibrate ($199/month program fee + medication costs separately), MEDVi's bundled pricing is simpler and potentially cheaper depending on medication source.

What do we like about MEDVi?

Bundled pricing transparency. One monthly price covers physician visits, medication, and coaching. No separate membership fees, no hidden costs beyond lab work. This is simpler than Mochi's two-part pricing model.

Video physician consultations every 4-6 weeks. In a market dominated by async questionnaires, regular video visits with a board-certified physician represent meaningfully more clinical depth. Patients can discuss side effects, dosing adjustments, and progress face-to-face.

Metabolic coaching included. Monthly coaching sessions covering nutrition, exercise, and behavioral strategies go beyond pure medication delivery. This is table stakes for premium platforms like Calibrate but rare at MEDVi's price point.

Both compounded and brand options. Patients can start on compounded medications and transition to brand-name through insurance if coverage is available — without changing providers.

What concerns us about MEDVi?

Mixed patient reviews. ConsumerAffairs and other review platforms show genuinely mixed feedback. Some patients report billing issues (unexpected charges, difficulty canceling), inconsistent shipping timelines, and communication gaps. Others report strong results and positive provider experiences. The inconsistency suggests growing pains for a young company.

Company maturity. Founded in 2022, MEDVi is still a young telehealth startup. The "concierge" branding sets high expectations that a company of this size may struggle to consistently deliver. We recommend tempering expectations — this is a well-intentioned mid-tier telehealth service, not a white-glove concierge medicine practice.

Compounding risk. Like all providers offering compounded GLP-1 medications, MEDVi faces the evolving FDA enforcement landscape. The FDA has issued thousands of warning letters to compounding pharmacies and telehealth companies since September 2025. Patients should ask MEDVi directly about their compounding pharmacy partnerships and regulatory standing.

Lab work not included. For a platform positioning itself as clinically comprehensive, the absence of included lab work is a notable gap. Calibrate includes lab panels; MEDVi does not. Metabolic health monitoring without baseline labs is incomplete.

Tirzepatide pricing is high. At $349/month for compounded tirzepatide, MEDVi is more expensive than most competitors. The April 2026 GlobeNewsWire article claiming MEDVi is the "most affordable tirzepatide" warrants scrutiny — the first-month promotional price of $279 is competitive, but the standard ongoing price is not.

What about MEDVi's compounded medications?

MEDVi's compounded medications are the primary draw for cash-pay patients. But the regulatory landscape has shifted significantly:

• Orforglipron is awaiting FDA approval (PDUFA April 10, 2026) at $149/month — would be cheaper than MEDVi's compounded semaglutide and fully FDA-approved
• The FDA continues enforcement against compounding pharmacies, though mass shutdowns have not materialized
• Hims exited compounding entirely in April 2026, signaling the market direction

For patients considering MEDVi's compounded options, the key question is whether the clinical extras (video visits, coaching) justify the $50/month premium over Ro's compounded semaglutide — or whether switching to a $149/month FDA-approved option like oral Wegovy, or waiting for orforglipron (PDUFA April 10, 2026), is the better move. Patients wondering about the cheapest way to get semaglutide online will find Ro or Henry Meds more competitive on price alone.

Who is MEDVi best for?

• Patients who want more clinical support than Ro or Henry Meds but can't afford Calibrate's program fee plus separate medication costs
• Patients who value video consultations — if face-to-face interaction with your prescribing physician matters, MEDVi offers this where most budget competitors don't
• Patients interested in compounded tirzepatide with coaching — few platforms bundle tirzepatide with regular physician visits at this price point

Who should look elsewhere?

• Budget-focused patients — Ro ($149/mo) or Henry Meds ($119/mo) are cheaper for compounded semaglutide
• Patients who want FDA-approved medications only — Consider oral Wegovy ($149-$199/mo), orforglipron ($149/mo announced, PDUFA April 10, 2026), or Hims (brand Wegovy via Novo Nordisk)
• Patients who need comprehensive clinical programs with labs — Calibrate includes lab panels, a year-long curriculum, and obesity medicine specialists
• Risk-averse patients — Given MEDVi's mixed reviews and young company status, patients who prioritize track record should consider established platforms

Is MEDVi worth it?

MEDVi is a legitimate mid-tier GLP-1 telehealth provider that offers more clinical depth than budget platforms at a reasonable price premium. The bundled pricing model is transparent, and the inclusion of video physician visits and metabolic coaching is genuine value.

But the "concierge" positioning oversells the experience. Mixed patient reviews, no included lab work, and the inherent uncertainty of compounded GLP-1 medications all temper our enthusiasm. We rate MEDVi 3.5/5 — a solid option for the right patient, but not a standout in an increasingly competitive market.

If you're choosing between MEDVi and a budget provider, the $50/month premium for video visits and coaching is reasonable if you'll actually use those services. If you're choosing between MEDVi's compounded semaglutide and oral Wegovy at $149/month (or orforglipron once it receives FDA approval), the case for MEDVi is harder to make on medication value alone — though the coaching component may tip the scales. For most patients asking whether MEDVi is worth it, the honest answer is: it depends on whether you'll actually attend those coaching sessions.

Frequently Asked Questions

Is MEDVi legit? Yes. MEDVi is a LegitScript-certified telehealth company operating with licensed physicians. It is a younger company (founded 2022) with mixed reviews — some patients report billing issues and shipping inconsistencies, while others report strong clinical experiences.

How much does MEDVi cost per month? $199/month for compounded semaglutide and $349/month for compounded tirzepatide (first month may be $279 promotional). Both prices include physician visits and metabolic coaching. Lab work is an additional cost.

Does MEDVi take insurance? MEDVi accepts insurance for brand-name GLP-1 medications (Wegovy, Zepbound) but not for compounded medication programs. HSA/FSA cards are accepted.

How do I cancel MEDVi? Contact MEDVi's support team to cancel. Multiple patient reviews mention billing continuing after cancellation requests — confirm in writing and follow up if charges continue.

Is MEDVi's semaglutide FDA-approved? No. MEDVi's compounded semaglutide is not FDA-approved as a finished drug product. The active ingredient is the same as Wegovy, but compounded formulations have not individually undergone FDA review. Brand-name Wegovy and Zepbound (available through MEDVi with insurance) are FDA-approved.

How does MEDVi compare to Ro? Ro charges $149/month for compounded semaglutide with no video visits or coaching. MEDVi charges $199/month but includes video physician consultations and metabolic coaching. The $50/month premium is worth it if you'll use those services; if you just want medication access, Ro is cheaper.

Is MEDVi a good option for getting GLP-1 without insurance? It is an option, though not the cheapest. For cash-pay patients asking how to get GLP-1 without insurance, Ro ($149/mo) and Henry Meds ($119/mo) offer lower prices for semaglutide without coaching or video visits.

Related Content

• MEDVi Provider Profile — Company details and full pricing
• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• Cheapest GLP-1 Providers — Budget options compared
• Mochi Health Review — Similar mid-tier competitor
• Calibrate Review — Premium program comparison
• MEDVi vs Calibrate — Side-by-side comparison
• GLP-1 Cost & Insurance FAQ — What you'll actually pay

This review is for informational purposes only and does not constitute medical advice. MEDVi review based on publicly available pricing, patient reviews, and platform analysis as of April 2026. Pricing and services may change — confirm directly with MEDVi before enrolling. Last updated March 28, 2026.

Data Sources & Methodology

Pricing and protocol data sourced from Medvi's public website and verified via checkout flow, April 2026. Patient experience data drawn from public reviews (Google, Trustpilot, Reddit) and independent patient outreach. Telehealth Ally has no commercial relationship with this provider. Rankings and ratings are editorial-only.